A value-based approach to healthcare is gradually gaining traction in Taiwan, as the country’s healthcare system confronts the opportunities and pressures of innovative new medical treatments along with a growing burden of both chronic and infectious diseases.
Any efforts to move Taiwan along in the process of establishing value measures will need to look at several key issues that have an impact on the future course of value-based healthcare: how the country’s healthcare decision-making institutions interpret value; who the main stakeholders with an input into the decision-making process are and should be; and what aspects of healthcare can logistically be evaluated within a value-based framework. In addition, experts say the health system will need to find ways to use its health technology assessment (HTA) capabilities to identify low-value areas where it is prudent to reduce investment in order to free up resources for more cost-effective expenditures. This process will require a more integrated use of HTA to evaluate not only medical treatments and devices, but entire care pathways.